CAPS-1 Inhibitors
Chemical inhibitors of CAPS-1 operate through diverse mechanisms to impair its function in vesicle trafficking and neurotransmitter release. Bafilomycin A1 and Concanamycin A target V-ATPases, which are fundamental for creating the acidic environment within vesicles that CAPS-1 requires to prime vesicles for neurotransmitter loading and release. The inhibition of V-ATPases leads to less acidic vesicles, impeding CAPS-1's ability to facilitate neurotransmitter uptake into the vesicles, thus inhibiting its function. Tetanus Toxin and Botulinum Toxin A exert their inhibitory effects by cleaving SNARE proteins, essential components of the vesicle fusion machinery. Given that CAPS-1 is closely associated with SNARE-mediated vesicle fusion, the cleavage of SNARE proteins interrupts the final steps of vesicle docking and fusion, thereby inhibiting CAPS-1's role in neurotransmitter release.
Dynamin, a GTPase involved in vesicle scission, is inhibited by Dynasore, which affects vesicle recycling and, as a result, CAPS-1-dependent neurotransmitter release. Similarly, Endosidin 2 and Exo1 disrupt the trafficking and docking of vesicles, respectively, by affecting ARF-GEF proteins and the exocyst complex, further inhibiting CAPS-1 activity in vesicle exocytosis. Latrunculin A and Jasplakinolide disrupt the actin cytoskeleton by either preventing actin polymerization or stabilizing actin filaments, respectively, which are both crucial for the CAPS-1-mediated vesicle transport process. Lastly, Nocodazole and Colchicine hinder microtubule function by binding to tubulin, which is essential for vesicle transport along microtubules. The disruption of microtubule dynamics by these chemicals inhibits CAPS-1's role in vesicle delivery to the plasma membrane, further inhibiting the function of CAPS-1 in neurotransmitter release.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Bafilomycin A1 inhibits V-ATPases, which are necessary for vesicle acidification. CAPS-1 requires acidic vesicles to promote neurotransmitter release, so inhibition of V-ATPases by Bafilomycin A1 would result in functional inhibition of CAPS-1 by preventing proper vesicle acidification. | ||||||
Concanamycin A | 80890-47-7 | sc-202111 sc-202111A sc-202111B sc-202111C | 50 µg 200 µg 1 mg 5 mg | $66.00 $167.00 $673.00 $2601.00 | 109 | |
Concanamycin A is also a V-ATPase inhibitor, impairing vesicle acidification. By disrupting this process, Concanamycin A would prevent CAPS-1 from functioning properly as it relies on the acidic environment for neurotransmitter loading. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
Dynasore inhibits dynamin, a GTPase involved in vesicle scission. Since CAPS-1 is implicated in vesicle trafficking and release, inhibition of dynamin would disrupt vesicle recycling and, consequently, CAPS-1-dependent neurotransmitter release. | ||||||
Exo1 | 461681-88-9 | sc-200752 sc-200752A | 10 mg 50 mg | $84.00 $297.00 | 4 | |
Exo1 inhibits the exocyst complex, a key player in tethering vesicles to the plasma membrane. Since CAPS-1 is essential for vesicle exocytosis, inhibition of the exocyst complex would impair the vesicle docking process, thereby inhibiting CAPS-1 function. | ||||||
Latrunculin A, Latrunculia magnifica | 76343-93-6 | sc-202691 sc-202691B | 100 µg 500 µg | $265.00 $815.00 | 36 | |
Latrunculin A binds to actin monomers and prevents polymerization. The actin cytoskeleton is important for vesicle transport, so inhibition of actin polymerization by Latrunculin A would impede vesicle mobility and inhibit CAPS-1 function. | ||||||
Jasplakinolide | 102396-24-7 | sc-202191 sc-202191A | 50 µg 100 µg | $184.00 $305.00 | 59 | |
Jasplakinolide stabilizes actin filaments and prevents their dynamics. Since CAPS-1-dependent vesicle transport requires dynamic actin structures, stabilization of actin filaments would disrupt this process and inhibit CAPS-1 function. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Nocodazole disrupts microtubules by binding to tubulin. Microtubule dynamics are crucial for vesicle transport, and disruption by Nocodazole would inhibit CAPS-1 function by impeding vesicle delivery to the plasma membrane. | ||||||
Colchicine | 64-86-8 | sc-203005 sc-203005A sc-203005B sc-203005C sc-203005D sc-203005E | 1 g 5 g 50 g 100 g 500 g 1 kg | $100.00 $321.00 $2289.00 $4484.00 $18207.00 $34749.00 | 3 | |
Colchicine binds to tubulin and inhibits microtubule polymerization. As CAPS-1 is involved in vesicle transport along microtubules, inhibition of microtubule formation by Colchicine would functionally inhibit CAPS-1 by blocking vesicle transport pathways. | ||||||